article
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders…
29 July 2024 | By Dennis Pedersen (Commit Biologics), Drug Target Review, Krishna Polu (Commit Biologics)
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders of Commit Biologics, which is backed by Novo Holdings and Bioqube Ventures, elucidate how their technology differs from other existing therapeutic platforms and highlight its implications for the treatment of both cancer and autoimmune disease.